HPV-based cervical cancer screening in Nicaragua: from testing to treatment

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[2] Ferlay J(2008)Overview of human papillomavirus-based and other novel options for cervical Cancer screening in developed and developing countries Vaccine. 26 K29-K41

[3] Soerjomataram I(2006)Overview of the European and north American studies on HPV testing in primary cervical cancer screening Int J Cancer 119 1095-1101

[4] Siegel RL(2005)The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice JNCI J Natl Cancer Inst 97 1072-1079

[5] Torre LA(2018)Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses BMJ. 363 k4823-e94

[6] Jemal A(2016)HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study BMJ. 353 i2823-138

[7] Cuzick J(2015)Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial Lancet Glob Health 3 e85-1799

[8] Arbyn M(2016)A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC) Health Technol Assess Winch Engl 20 1-1816

[9] Sankaranarayanan R(2010)Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings J Infect Dis 202 1789-e783

[10] Cuzick J(2005)A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica J Infect Dis 191 1808-76

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[2] Ferlay J(2008)Overview of human papillomavirus-based and other novel options for cervical Cancer screening in developed and developing countries Vaccine. 26 K29-K41

[3] Soerjomataram I(2006)Overview of the European and north American studies on HPV testing in primary cervical cancer screening Int J Cancer 119 1095-1101

[4] Siegel RL(2005)The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice JNCI J Natl Cancer Inst 97 1072-1079

[5] Torre LA(2018)Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses BMJ. 363 k4823-e94

[6] Jemal A(2016)HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study BMJ. 353 i2823-138

[7] Cuzick J(2015)Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial Lancet Glob Health 3 e85-1799

[8] Arbyn M(2016)A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC) Health Technol Assess Winch Engl 20 1-1816

[9] Sankaranarayanan R(2010)Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings J Infect Dis 202 1789-e783

[10] Cuzick J(2005)A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica J Infect Dis 191 1808-76